Thursday, April 15, 2021

FDA Issues Notices Regarding Premarket Notification (510(k)) Requirements for Certain Class I, Class II and Unclassified Medical Devices

Two new Federal Register notices address premarket notification requirements (510(k)) for certain class I, class II and unclassified medical

If your email program has trouble displaying this email, view as a webpage.

US Food and Drug Administration

FDA Issues Notices Regarding Premarket Notification Requirements for Certain Class I, Class II and Unclassified Medical Devices

On January 15, 2021, the Department of Health and Human Services (HHS) issued a notice in the Federal Register determining certain class I reserved devices to be exempt from premarket notification (also known as 510(k)) and proposing to exempt certain class II devices, along with one unclassified device type, from premarket notification.

Today, in the interest of public health, HHS and the U.S. Food and Drug Administration (FDA) issued two notices in the Federal Register to explain HHS's and FDA's current view on the requirement for premarket notification for the medical devices included in the January 15, 2021, notice.

First Notice: Medical Devices; Class I Surgeon's and Patient Examination Gloves

This notice explains that the class I surgeon's and patient examination gloves identified in the January 15, 2021 notice meet the "reserved" criteria in the statute and thus will require premarket notification. Comments on this notice may be submitted to the Federal Register docket within the 30-day open comment period.

Read the first notice

Second Notice: Making Permanent Regulatory Flexibilities Provided During the COVID-19 Public Health Emergency by Exempting Certain Medical Devices from Premarket Notification Requirements; Withdrawal of Proposed Exemptions 

This notice withdraws the proposed exemptions for the 83 class II devices and one unclassified device type that HHS included in the January 15, 2021, notice. The devices within the scope of this notice will continue to be subject to premarket notification.

Read the second notice

COVID-19 Enforcement Policies

The FDA issued enforcement policies concerning certain devices in response to the COVID-19 public health emergency. These policies do not alter the legal obligation to comply with the relevant legal requirements and do not preclude the FDA from taking action to enforce those requirements where appropriate. Those policies, which are limited to the public health emergency and include risk mitigations, are different from the January 15, 2021, notice.

Complying with Applicable Regulatory Requirements

Establishments seeking to market the Class I reserved devices classified with product codes OPC, LZC, OPH, OPA, OIG, LYY, and LYZ should comply with applicable regulatory requirements, including labeling and requirements for import into the United States.

More information about premarket notification is available on the Premarket Notification 510(k) page.

Questions?

If you have questions about these notices or premarket notification, contact the Division of Industry and Consumer Education.


This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration · 
10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA
GovDelivery logo

No comments:

Post a Comment